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Abstract 
The present work aims at the formulation development and 
evaluation of Tramadol Hydrochloride orally disintegrating tablets 
using galen IQ as a diluent. galen IQ, official as Isomalt doesn’t have 
much  generation of data with respect to its functionality. Attempts 
were made to prepare binder-free, 250 mg Tramadol Hydrochloride 
orally disintegrating tablets using different concentrations of 
Crospovidone, Croscarmellose Sodium, Sodium Starch Glycolate 
and Starch 1500 as disintegrants in different combinations by direct 
compression method. Tramadol Hydrochloride is a water soluble 
drug and the dose taken was 50 mg. Preformulation studies on 
Tramadol Hydrochloride were carried out, followed by excipient 
compatibility studies between the drug , galen IQ and other 
excipients being used in the formulation. Spectroscopic studies were 
also conducted in order to deduce out the λmax (lambda-max).A total 
of ten formulations (F1 to F10) were developed .F10 batch was 
found to give best results on the basis of disintegration time of 21 
seconds. The powdered blend of F10 was evaluated for flow 
properties. The tablets of F10 batch were also evaluated for post 
compression tests like hardness, friability, weight variation, wetting 
time, water absorption ratio, content uniformity, assay, disintegration 
time and dissolution which were found to be within the prescribed 
limits. The tablets of F10 batch were also compared with the 
marketed formulation and were found to show pharmaceutical 
equivalence with a similarity factor (f2) of 85.72.All this work 
suggested that galen IQ could be successfully used as a diluent in the 
formulation of Tramadol Hydrochloride orally disintegrating tablet. 
Keywords: Tramadol Hydrochloride, galen IQ, Orally 
Disintegrating Tablet. 
Introduction 
Today drug delivery companies are focusing on 
solid oral drug delivery systems that offer greater 
patient compliance and effective dosages. Oral 
route is undoubtedly the most important drug 
delivery route which offers various advanteges of 
convenience of self administration and easy 
manufacturing along with saving costs .[1]  
Nowadays, a lot of patients find it difficult to 
swallow tablets and thus skip their prescribed 
medication, thus resulting in ineffective therapy. 
The difficulty is experienced in particular by 
pediatric and geriatric patients, but it also applies 
to people who are ill in bed and to those active 
working patients who are busy or traveling, 
especially those who have no access to water. [2] 
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Orally disintegrating tablets offer an advantage 
for populations who have difficulty in 
swallowing. It has been reported that Dysphagia 
(difficulty in swallowing) is common among all 
age groups and more specific with pediatric, 
geriatric population along with institutionalized 
patients and patients with nausea, vomiting, and 
motion sickness complications. ODTs with good 
taste and flavor increase the acceptability of bitter 
drugs by various groups of population.[3] 
 
To fulfill these medical needs, pharmaceutical 
technologists have developed a novel oral dosage 
form known as Orally Disintegrating Tablets 
(ODTs). [4], [5]. 
 
The US Food and Drug Administration Center 
for Drug Evaluation and Research (CDER) 
defines, in the ‘Orange Book’, an ODT as “a 
solid dosage form containing medicinal 
substances, which disintegrates rapidly, usually 
within a matter of seconds, when placed upon the 
tongue”.[6] 
 
Over a decade, the demand for development of 
orally disintegrating tablets (ODTs) has 
enormously increased as it has significant impact 
on the patient compliance. For both brand and 
generic companies, one of the most attractive and 
fastest-growing segments of the $30+ billion oral 
drug delivery market is orally disintegrating 
tablets (ODT). Since ODT technologies entered 
the market in the 1980s, they have grown steadily 
in demand and importance, and their product 
pipeline is rapidly expanding. In 2004, ODT 
products generated revenues of well over $2 
billion, an increase of 20% over 2003, according 
to a 2005 report by Technology Catalysts 
International .The market continues to grow 20% 
each year, with a growing penetration of generic 
ODTs. One of the most successful ODT products 
is GlaxoSmithKline’s Zofran® ODT 
(ondansetron) an anti-emesis drug for reactions to 
surgery, chemotherapy, and radiation. Zofran® 
ODT, approved in 1999,had worldwide sales in 
2004 of more than $300 million (representing 
20% of total Zofran sales), with average annual 
growth of nearly 50%. The product is also a good 
example GSK’s strategy of offering multiple 
dosage form choices to patients. [7]  
 
With this background the aim of the present 
investigation was to formulate and evaluate orally 
disintegrating tablet of Tramadol Hydrochloride. 
Tramadol Hydrochloride -( 1 RS; 2RS ) -2 -[ ( 
dimethylamino ) methyl] -1 -(3 -ethoxyphenyl) 
cyclohexanol hydrochloride is an analgesic which 
is  effective for intense and moderately intense 
pain. It is Class I drug and gets rapidly absorbed 
after oral administration by showing a 
bioavailability of 75%. It undergoes metabolism 
and has a half life of 6 to 7 hours.It is excreted 
out through renal administration. However, the 
very high water solubility of this active 
ingredient has prevented the successful 
development of tablets which disintegrate 
rapidly. For example, if Tramadol HCl is mixed 
with an insoluble excipient such as calcium 
dihydrogen phosphate and super disintegrating 
agent such as Kollidon CL and granulated, the 
resulting tablets, show a hardness of about 80 N, 
which require 5 minutes for complete 
disintegration. Disintegration cannot be 
accelerated by increasing the content of 
disintegrating agent. Hence, Tramadol 
Hydrochloride is formulated in the form of binder 
free tablets.[8]               
                    
The present work also involves exploration of 
novel multifunctional polymer galen IQTM for 
which not much data is available. galen IQ is 
official as Isomalt in European Pharmacopoeia 
and United States Pharmacopoeia-National 
Formulary. Isomalt ,a sugar alcohol, is an 
equimolecular mixture of two stereoisomers: α-
Dglucopyranosyl-1,1-D-mannitol (GPM) and α-
Dglucopyranosyl-1,6-D-sorbitol (GPS). Due to 
its properties such as taste, mouth feel, low 
calorie content, acariogenicity, suitability to 
diabetics and low hygroscopicity, it offers several 
advantages over most polyols when formulated in 
pharmaceutical dosage forms, particularly when 
used as a tablet excipient.[9]         
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The use of superdisintegrants provides an instant 
disintegration of the tablet as soon as it is placed 
on the tongue, thus the drug being released in the 
saliva. Thus, disintegrants like Crospovidone, 
Croscarmellose Sodium, Sodium Starch 
Glycolate and Starch 1500 are frequently used for 
the preparation of orally disintegrating 
tablets.[10] 
 
Materials and Methods 
Materials 
All the materials used in the present research 
work were commercial samples. 
 
Table 1: List of Materials and Equipments to be used. 
S.No. Name Source Functionality 
A. Drug/API 
1. Tramadol 
Hydrochloride 
Wanbury 
Limited 
Active 
Ingredient 
B. Polymers 
1. galen IQ BENEO-
Palatinit 
Diluent 
2. Crospovidone BASF Disintegrant 
3. Sodium Starch 
Glycolate 
 Disintegrant 
4. Starch 1500 Colorcon Disintegrant 
5. Croscarmellose 
Sodium 
 Disintegrant 
C. Chemicals 
1. Aerosil Sisco 
Research 
Lab 
Glidant 
2. Magnesium 
Stearate 
Central Drug 
House(CDH) 
Lubricant 
3. Talc LOBA 
Chemie 
Anti caking 
agent 
4. Sucralose  Sweetner 
 
Methods 
Preformulation Studies 
API Characterization 
a. Micromeritics 
The powder of Tramadol Hydrochloride was 
characterized by Angle of Repose, Bulk density, 
Tapped Density, % Compressibility (Carr’s 
Index) and Hausner Ratio.  
i. Angle of Repose (θ) 
It is defined as the maximum angle possible 
between the surface of a pile of powder and the 
horizontal plane. 
 
Angle of Repose was calculated using the 
formula: Tan θ = 2h/D or [θ = Tan-1(2h/D)] 
Where, θ = Angle of repose, h = height of the pile 
and D = Diameter of heap (plane surface 
occupied by the powder) 
 
ii. Bulk Density (Db) 
It is the ratio of total mass of powder to the bulk 
volume.  
Bulk density (expressed in gm/ml) was calculated 
according to formula mentioned below: 
 
Db= M/V0, where, M = Mass of the Powder and 
V0= Bulk volume of the powder. 
 
iii. Tapped Density (Dt) 
It is the ratio of total mass of powder to the taped 
volume of powder. 
 
Tapped density (expressed in gm/ml) was 
calculated according to formula mentioned 
below: 
 
Dt= M/Vt where, M = Mass of the Powder and 
Vt= Tapped volume of the powder.
 
 
iv. Compressibility Index (Carr’s 
Consolidation Index) 
It was calculated by using the formula: 
% Compressibility = [Tapped Density – Bulk 
Density/Tapped Denstiy] x 100  
 
v. Hausner Ratio 
Hausner Ratio is an indirect index of ease of 
powder flow. If the Hausner ratio of powder is 
near to 1.25, it indicates better powder flow. 
Hausner Ratio is calculated by the formula  
Hausner Ratio = Dt/ Db 
 
Where, Db = Bulk Density of Powder and Dt = 
Tapped Density of the Powder 
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b. Microscopic Evaluation of Tramadol 
Hydrochloride 
Optical Microscopy was employed to 
characterize the nature (Amorphous or 
Crystalline) of Tramadol Hydrochloride and to 
calculate certain parameters such as Particle 
Area, Particle Perimeter and Particle Size. Small 
amount of API was dispersed in a Light Liquid 
Paraffin in a watch glass. A drop of this solution 
was put on a glass slide with a cover slip and the 
slide was viewed using optical microscope. The 
required parameters were measured and 
calculated out with the help of Photomicroscope 
(MOTIK software), Stage micrometer and eye 
piece micrometer. 
 
c. Optical Rotation of Tramadol 
Hydrochloride 
Based on the solubility profile of the API, 
Distilled water was selected to be the solvent. A 
5% solution of API in water was prepared and 
maintained at a temperature of 25° C with the 
help of an Ice Bath. The solution was poured in 
the Polarimeter tube and analyzed for optical 
rotation.  
 
d. Melting Point Determination 
Melting Point was determined by taking small 
amount of Tramadol Hydrochloride in a capillary 
tube closed at one end. The capillary tube was 
placed in an electrically operated Digital Melting 
Point apparatus and the temperature (range) at 
which the drug melted was recorded. 
 
e. Test of Chlorides 
The test to check for the presence of chlorides 
was performed according to the IP procedure.  
Small amount of drug was dissolved in 2 ml of 
water in order to form a clear solution. The 
solution was then acidified with dilute nitric acid 
followed by addition of Silver nitrate 
solution.The solution was shaken and allowed to 
stand and checked for the presence of curdy 
white precipitates.The presence of curdy white 
precipitates confirmed the presence of chlorides 
in Tramadol Hydrochloride. 
 
f. FTIR–Spectroscopy and Excipient 
Compatibility Studies 
FTIR Study was employed to characterize the 
functional groups present in the Tramadol 
Hydrochloride, galen IQ and other excipients 
from the obtained Principal Peaks and to 
ascertain the compatibility between Tramadol 
Hydrochloride and our main polymer of interest 
(galen IQ). In the preparation of tablets 
formulation, polymer of interest (galen IQ) may 
not only interact with the API (Tramadol 
Hydrochloride) but also with the other excipients 
used in the formulation process. Since galen IQ 
will be in close contact with the drug and other 
excipients, it could lead to instability of the 
formulated preparation(ODT). 
 
Hence, Preformulation studies regarding the 
drug-polymer and polymer-polymer are critical. 
Potassium Bromide was kept for drying in an 
oven for 100 ° C and cooled. Potassium Bromide 
Pellet was prepared and background scan was 
performed.Potassium Bromide was mixed with 
drug and /or Polymer in 100:1 ratio and the 
sample scan was performed between 4000-400 
nm.. The Spectras obtained were compared with 
each other. Disappearance of peaks or shifting of 
peak in any of the spectra was studied. 
 
Spectroscopic Studies 
a. Detection of analytical wavelength λmax 
A 200 ppm solution was prepared by dissolving 
20 mg in water/ Dissolution Media (0.1 N HCl) 
in a 100 ml volumetric flask. The solution was 
sonicated and the volume was made upto 100 ml. 
The solution was scanned between 400 – 200 nm 
(UV range). 
 
b. Calibration Curve of Tramadol 
Hydrochloride 
Solvents Selected: Water, Methanol and 0.1 N 
HCl. 
Accurately weighed quantity Tramadol 
Hydrochloride (10 mg) was weighed and 
dissolved in small quantity of the solvent in a 100 
ml volumetric flask.The solution was sonicated 
and the volume was made up to 100 ml with the 
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same solvent to form the Stock Solution (100 
ppm). 
 
Using, the stock solution, appropriate aliquots 
were taken into different volumetric flasks and 
the volume was made upto 10 ml using the 
solvent so as to get drug concentrations of 20,40 
60,80 and 100 ppm.The absorbances of these 
drug solutions were estimated at λmax .This 
procedure was performed for each of the solvent 
separately and in triplicate to validate the 
calibration curve.  
 
20 mg of Tramadol Hydrochloride Dissolved in 
100 ml (Stock Solution: 100 ppm) 
 
                                     Aliquots taken and Volume made upto 10 ml 
        
 
  2 ml                4 ml                      5 ml                 6 ml                        8 ml                  10 ml 
 
       20 ppm           40 ppm               50 ppm           60 ppm                    80 ppm           100 ppm 
 
 
Formulation Development of Orally Disintegrating Tablets of Tramadol  Hydrochloride 
 
Table 2: Composition for ODT (mg/tablet) of Tramadol Hydrochloride (50 mg). 
Sr.No  Formulation  F1  F2  F3  F4  F5  
1.  Tramadol Hydrochloride  50  50  50  50  50  
2.  Cross Povidone(CP)  -  7.5(3%) 10(4%)  -  12(4%)  
3.  Cross Carmelose Sodium (CCS)  -  -  -  -  -  
4.  Starch 1500  7.5 (3%)  -  -  10(4%)  -  
5.  Sodium Starch Glycolate (SSG)  10 (4%) 10 (4%)  15(6%)  15(6%)  18(6%)  
6.  galen IQ  176.25  176.25  167.5  167.5  211  
7.  Talc  2.5  2.5  2.5  2.5  3.0  
8.  Aerosil  -  -  1.25  1.25  3.0  
9.  Sucralose  1.25  1.25  1.25  1.25  1.5  
10.  Magnesium Stearate  2.5  2.5  2.5  2.5  1.5  
 Total Weight  250  250  250  250  300  
 
Table 3: Composition for ODT (mg/tablet) of Tramadol Hydrochloride (50 mg). 
Sr.No  Formulation  F6  F7  F8  F9  F10  
1.  Tramadol Hydrochloride  50  50  50  50  50  
2.  Cross Povidone(CP)  -  12.5(5%)  15(6%)  -  10(4%)  
3.  Cross Carmelose Sodium (CCS)  -  -  -  10(4%)  -  
4.  Starch 1500  12(4%)  -  -  -  -  
5.  Sodium Starch Glycolate(SSG)  18(6%)  12.5(5%)  10(4%)  15(6%)  15(6%)  
6.  galen IQ  211  165  165  165  165  
7.  Talc  3.0  2.5  2.5  2.5  2.5  
8.  Aerosil  3.0  2.5  2.5  2.5  2.5  
9.  Sucralose  1.5  2.5  2.5  2.5  2.5  
10.  Magnesium Stearate  1.5  2.5  2.5  2.5  2.5  
 Total Weight  300  250  250  250  250  
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Procedure: Each tablet containing 50 mg of 
Tramadol Hydrochloride was prepared by direct 
compression as per the formulas given in the 
Table 2 and 3. The superdisintegrants–
Crospovidone (3%, 4%, 5%and 6 %) 
Croscarmellose Sodium (4%), Starch 1500(3% 
and 4%) and Sodium Starch Glycolate (4%, 5% 
and 6%) were used in different proportions and 
different combinations. All the ingredients were 
passed through sieve # 52 and accurately 
weighed. The drug, superdisintegrants, Aerosil 
and Sucralose were mixed by geometric dilution 
method to improve the drug distribution and 
content uniformity.  Then Magnesium stearate 
and talc were passed through sieve # 100, mixed 
and blended well with the initial mixture. The 
mixed blend of drug and the excipients was 
compressed using Rimek Minipress rotary 
punching machine to produce a tablet weighing 
250 mg having a diameter of 9.5 mm. Following 
the above procedure 10 batches of orally 
disintegrating Tablets of Tramadol Hydrochloride 
in different ratios of superdisintegrants were 
prepared. 
 
Characterization of Orally Disintegrating 
Tablets of Tramadol Hydrochloride 
a. Thickness and Dimension 
Five tablets of each batch were selected and 
measured for the thickness and diameter using 
Vernier Calliper. The extent to which the 
thickness of each tablet deviated from ± 5% of 
the standard value was determined. 
 
b. Hardness of the Tablets 
Hardness (diametric crushing strength) is a force 
required to break a tablet across the diameter. 
The hardness was tested using Monsanto tester. 
“Hardness Factor”, the average of the three 
determinations, was determined and reported. 
The force was reported in kilograms per 
centimeter square. 
 
c. Friability of Uncoated Tablets 
Friability is the loss of weight of tablet in the 
container/ package due to removal of fine 
particles from the surface. Permitted Friability 
limit is 1.0 %. 
 
26 tablets were weighed collectively and placed 
in the chamber of the friabilator. In the 
friabilator, the tablets were exposed to rolling, 
resulting from free fall of tablets within the 
chamber of the friabilator. It was rotated at a rate 
of 25 rpm. After 100 rotations (4 minutes), the 
tablets were taken out from the friabilator and 
intact tablets were again weighed collectively. 
The percent friability was determined using the 
following formula: 
 
  
 
Where, W1 = Weight of the Tablets before the 
Test and W2 = Weight of the Tablet after the Test 
 
d. Weight Variation Test 
Twenty Tablets were weighed individually and 
all together. Average weight was calculated from 
the total weight of all tablets. The individual 
weights were compared with the average weight. 
The percentage difference in the weight variation 
should be within the permissible limits (± 5%). 
The percent deviation was calculated using the 
following formula: 
 
Percentage Deviation = 
       = Indiviual Weight - Average Weight x 100 
 Average Weight 
 
Any variation in the weight of tablet (for any 
reason) leads to either under medication or over 
medication. So, every tablet in each batch should 
have a uniform weight. Deviation within the IP 
limits of 5% is allowed as the tablet weighed 250 
mg. 
 
e. Drug Content Estimation (Assay) 
Two uncoated tablets were selected randomly and 
average weight was calculated. Tablets were 
crushed in a mortar and accurately weighed 
amount of average tablet was taken from the 
crushed blend. Then the samples were transferred 
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to a 100 ml volumetric flask and the volume was 
made upto the mark with distilled water. The 
content was shaken periodically and kept for one 
hour to allow the drug to dissolve completely. 
The mixtures were filtered and appropriate 
dilutions were made by taking aliquots of 2.5 ml 
and 5 mlto give a concentration of 25 ppm and 50 
ppm respectively. The drug content in each tablet 
was estimated at λmax against blank reference and 
reported. A total of 5 samples (10 tablets) were 
subjected to this process.  
 
f. Uniformity of Content 
Ten Tablets were selected randomly and 
individually put in ten different 100 ml 
volumetric flasks. The volume was made upto the 
mark with distilled water. The content was 
shaken periodically and kept for one hour to 
allow the drug to dissolve completely. The 
solutions in each flask were filtered separately 
and appropriate dilutions of 50 ppm were made 
by taking an aliquot of 1 ml and diluting to 10 ml. 
The drug content in each tablet was estimated at 
λmax against blank reference and reported.Using 
the Regression equation obtained from 
calibration curve, the actual drug content was 
estimated.             
 
g. Wetting Time and Water Absorption Ratio 
Wetting Time of dosage form is related with the 
contact angle. Wetting time of the mouth 
dissolving tablets is another important parameter, 
which needs to be assessed to give an insight into 
the disintegration properties of the tablets; a 
lower wetting time implies a quicker 
disintegration of the tablet. The wetting time of 
the tablet can be measured using a simple 
procedure. A circular tissue paper of 10 cm 
diameter was placed in a petridish with a 10 cm 
diameter. Ten ml of water containing Potassium 
Permanganate was added to the Petridish. A 
tablet was carefully placed on the surface of the 
tissue paper. The time required for water to reach 
upper surface of the tablet is noted as the wetting 
time.  
 
Water absorption Ratio, R is calculated using the 
formula: 
 
R = 100 (Wa-Wb) / Wb where, Wb = Weight of 
the tablet before keeping in the petridish (in mg) 
and Wa = Weight of the wetted tablet in the 
petridish (in mg)
 
 
 
h. Disintegration Time 
The disintegration time for mouth dissolving 
tablet needs to be modified as disintegration is 
required without water, thus the test should 
mimic the disintegration in salivary content.For 
this USP Disintegration apparatus (Basket rack 
assembly) was used. Six tablets were put in the 
apparatus containing water maintained at 37 ± 5 
°C. The time taken by all the tablets to 
completely disintegrate into fine particles was 
noted. 
 
i. In vitro Drug Release Studies 
In vitro drug release studies were carried out by 
using USP Dissolution Apparatus I (Basket Type) 
at 100 rpm. The drug release profile was studied 
in 900 ml of 0.1 N HCl, maintained at    37 ± 5 
°C .Aliquots of 10 ml of dissolution medium 
were withdrawn at specific time intervals      (10 , 
20 ,30 and 45 minutes). The fresh dissolution 
medium was replaced every time with the same 
quantity (10 ml). The collected samples were 
analyzed at λmax using dissolution medium as 
blank. The cumulative percentage drug release 
was calculated. 
 
j. Micromeritc Study of the Powdered Blend 
was also performed . 
 
Comparison with the Marketed Product 
Following the procedure for in vitro drug release 
studies and the disintegration time, the drug 
release profile of marketed product of Tramadol 
Hydrochloride (TRAMBAXTM50) was also 
determined and compared with the best 
formulation among all the batches. 
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Results and Discussion 
Preformulation Studies 
The following Results were observed by performing Preformulation Studies on Tramadol Hydrochloride, 
galen IQ and other excipients. 
 
1. API Characterization 
a.Micromeritics  
 
Table 4: Data for Micromeritics Study of Tramadol Hydrochloride. 
Sr No.  Parameter  Observations  Flow Description  
1.  Loose Bulk Density (gm/cc)  0.5  -  
2.  Tapped Bulk Density (gm/cc)  0.555  -  
3.  Angle of Repose θ (°)  11.47  Good  
4.  Compressability Index (%)  10  Good  
5.  Hausner Ratio  1.11  Good  
 
 
b. Microscopic Evaluation of Tramadol Hydrochloride  
 
 
Fig 1: Microscopy showing Crystalline nature of the drug.                                                
 
Table 5: Particle Size Characterization of  Tramadol Hydrochloride. 
 
 
 
 
 
 
c. Optical Rotation, Melting Point and Chlorides Presence Test of Tramadol Hydrochloride. 
 
Table 6: Data for Optical Rotation, Melting Point and Chlorides Presence Test of drug. 
Sr No.  Parameters Observations 
1.  Optical Rotation -0.001 ,-0.003 
2.  Melting Point 182-184°C. 
3. Test of Chlorides Curdy White Precipitates 
 
Sr No  Parameters  Observations  
1. Average Particle Size 2.3 µm 
2.  Average Object Area  6.5 Sq.µm  
3.  Average Object Perimeter  5.7µm  
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The presence of white curdy precipitates was 
observed which proved that chlorides were 
present in the given drug sample. 
 
f. FTIR – Spectroscopy 
The FTIR spectrum of pure Tramadol 
Hydrochloride was shown in Figure 2 and 3 and 
peaks were listed in Table 7. The peaks given in 
Table 7 can be considered as characteristic peaks 
of Tramadol Hydrochloride. It was observed that 
these peaks were not affected by the presence of 
galen IQ as shown by the FTIR Spectra in 
Figure.3. This indicates that there is no 
interaction between Tramadol Hydrochloride and 
galen IQ. The galen IQ peaks were also not 
affected by the presence of other excipients as 
shown by the FTIR Spectra in Figure 4 to 8 and 
the data indicating that can be observed in Table 
8. It indicates that there is no interaction between 
galen IQ and other excipients and hence are 
highly compatible.  
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Fig 2: IR Spectrum of Tramadol Hydrochloride Fig 3: IR Spectrum of Tramadol Hydrochloride + galen IQ. 
 
 
Table 7: Data Obtained for IR Spectra of Tramadol Hydrochloride 
Ingredients                                         Principal Peaks (cm
-1
)  
Functional Groups C-H str  (aromatic) C-H str (alliphatic) N-H str C-N str C=C str C-O str 
Drug  2930.02  2668.0  3343.17  1289.46  1607.53  1218.28  
Drug+ galen IQ  2929.47  2673.01  3344.79  1289.45  1607.45  1217.65  
 
 
     
Fig 4: IR Spectrum of galen IQ.    Fig 5: IR Spectrum of galen IQ + Crospovidone. 
Chawla et al. International Journal of Drug Delivery 3 (2011) 439-455 
 
 
 
449
   
Fig 6: IR Spectrum of galen IQ+ SSG. 
 
  
Fig7: IR Spectrum of galen IQ + Magnesium Stearate. 
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Fig 8: IR Spectrum of galen IQ + Sucralose. 
 
Table 8: Data Obtained for IR Spectra of galen IQ. 
Functional Groups  C-H str (aromatic) C-H str  (alliphatic) O-H str  C-O-C   str  
galen IQ  2945.19  2345.41, 2364.35  3384.59  1156.28,1039.98  
galen IQ + Crospovidone  2939.72  -  3390.50  1153.77,1030.43  
galen IQ + Sodium Starch 
Glycolate   
2925.94  2163.91  3391.59  1154.62,1024.52  
galenIQ +Magnesium 
Stearate  
2918.08  -  3401.23  1155.16,1038.53  
galen IQ+ Sucralose  2924.58  2083.86  3390.05  1155.04,1038.12  
 
 It was observed that the aliphatic C-H stretching 
was missing in the combinations of galen IQ + 
Crospovidone and galen IQ +Magnesium 
Stearate. However, no physical instability was 
visible to the naked eye. 
 
2. Spectroscopic Studies 
a. Detection of analytical wavelength λmax 
The UV absorption spectra of Tramadol 
Hydrochloride showed a peak at 271 nm against 
reagent blank (water and 0.1 N HCl respectively) 
and the same was used as λmax for further analysis 
irrespective of the reagent / solvent being used. 
Therefore, Observed λmax = 271 nm. 
 
200.0 250 300 350 400.0
0.00
0.5
1.0
1.5
2.00
nm
A 
271.54,0.68444
    
Fig 8: UV Spectra in Water.  
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Fig 9: UV Spectra in 0.1 N HCl. 
 
Table 9: Calibration Curve Data for Tramadol Hydrochloride. 
Sr No. Absorbance at 271 nm 
 Concentration (in ppm) Water Methanol 0.1 N HCl 
1. 20 0.1014 0.1464 0.1078 
2. 40 0.2223 0.2555 0.2694 
3. 50 - - 0.3399 
4. 60 0.3242 0.3818 0.4201 
5. 80 0.4633 0.5045 0.5916 
6. 100 0.5559 0.6471 0.7290 
7. Regression Equation y=0.0057x-0.0055 y= 0.0063x + 0.0057 y=0.007x-0.0047 
8. Regression Coefficient(r2) 0.998 0.998 0.999 
 
  
       Fig 10: Standard Plot in Water                            
 
 
Fig11: Standard Plot in Methanol 
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Figure 12: Standard Plot in 0.1 N HCl. 
 
b. Calibration Curve of Tramadol 
Hydrochloride 
The data obtained by plotting the calibration 
curve are given in Table 9 and Fig 10 to Fig 12. 
The disintegration time for all the manufactured 
batches was studied and following results were 
obtained: 
 
 
 
 
 
Table 10: Evaluation of formulation trials in terms of 
Disintegration time. 
Formulation 
Trials  F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Disintegration 
time  
(in seconds)  
75 65 4 40 50 50 37 35 42 25 
Based on the observation in terms of 
disintegration time, following batches were 
proceeded with:  F3 and F10. 
 
However, Evaluation of F3 Batch showed that 
hardness /crushing strength= 1 Kg/cm2.Moreover, 
F3 Batch failed the Friability Test (Friability = 
1.5%).Hence the batch chosen was F10 
 
Evaluation of Results of Batch F10 
The F 10 Batch selected for evaluation contained 
Crospovidone (4%) and Sodium Starch glycolate 
(6%) as disintegrants. Result of all pre 
compression parameters evaluated were within 
prescribed limit and indicated good free flowing 
property which is described in Table 11.The data 
obtained from post compression parameter 
evaluated are shown in Table 12. 
Table 11: Result of micromeritic property/ precompression parameter of F10. 
Sr No.  Parameter  Observations  Flow Description  
1.  Loose Bulk Density (gm/cc)  0.496 - 
2.  Tapped Bulk Density (gm/cc)  0.581 - 
3.  Angle of Repose θ (°)  26.25 Good 
4.  Compressability Index (%)  14.62 Good 
5.  Hausner Ratio  1.17 Good 
 
Table 12: Result of post compression parameter of F10. 
Sr No.  Parameter  Observations  
1.  Disintegration Time ( 6 tablets) 21 seconds 
2.  Hardness 3 Kg/cm2 
3.  Friability 0.08% 
4.  Thickness (mm) 9.5 
5.  Diameter (mm) 3.6 
6. Weight Variation (in mg) 246.225 ± 12.311 
7. Uniformity of Content ( in ppm)  50± 7.5 
8. Assay  For 25 ppm: 25±0.25      For 50 ppm: 50± 0.5 
9. Wetting Time 18.65 seconds 
10. Water Absorption Ratio 8.1 
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Figure 13: Wetting time of tablet for F 10 Batch 
 
In Vitro Dissolution Study 
 
Table 13: Dissolution Conditions for In vitro Drug Release Study for Tablets of F 10  
Drug  Dosage 
form  
USP 
Apparatus  
Speed (Rpm)  Medium  Volume (ml)  Sampling Time 
Points  (mins)  
Tramadol HCl  Tablet  Type I (Basket) 100  0.1 N HCl  900  10, 20, 30 and 45  
 
Table 14: Data for in vitro Drug release profile 
Observations: 
Sr.No. Sampling Points (mins) % Cumulative Release 
1  10      88.54849 
2  20  92.3242 
3  30  95.41043 
4  45  95.36536 
 
 
Fig 14: % Cumulative Drug Release versus Time Points 
(in minutes). 
 
Comparison with the Marketed Product 
Orally Disintegrating Tablets were taken for 
comparison. These tablets were subjected to the 
evaluation of Organoleptic Properties, Physical 
Properties, disintegration time and Drug release 
Pattern. The results are shown as follows: 
 
Brand Name: TRAMBAXTM50   Company 
Name: Ranbaxy Laboratories                        
Labelled Claim: 50 mg Tramadol HCl 
 
 Table 15: Characterization of the marketed tablet. 
Sr.No Evaluation Observations 
1. Organoleptic 
Properties (Colour, 
Odour and Shape) 
White, Circular and 
Odourless Tablet 
2. Thickness 4.4 mm 
3. Diameter 12.2 mm 
4. Hardness 2 Kg/cm2 
5. Disintegration Time 21 seconds 
6. In vitro Drug Release 
Studies 
9658.% ( in 45 inutes) 
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Table 16: In Vitro Drug Release for Reproducible F10 Batch and Marketed Product 
Observations:                                      
Sr.No. Sampling Points (mins) % Cumulative Release 
( F10 Reproducible Batch) 
% Cumulative Release 
(Marketed Product) 
 1  10 88.54849 90.73 
2  20  92.3242 94.78 
3  30  95.41043 96.54 
4  45  95.36536 96.58 
 
 
 
Figure 15: In Vitro Comparative Drug Release Profile 
of Tramadol Hydrochloride ODT. 
Series I: Marketed Product   Series II: F10 Batch. 
 
Calculations were done and the following 
observations were made: Similarity factor (f2) = 
85.72. Comparative dissolution studies were done 
and f2 values were calculated according to the 
US FDA guidelines. As can be seen, f2 value of 
85.72 for batch F10 shows pharmaceutical 
equivalence to the marketed product of same 
strength.  
 
Conclusion 
All this work suggested that galen IQ can be 
successfully used as a diluent in the formulation 
of Tramadol Hydrochloride ODT. The procedure 
to manufacture ODT by direct compression was 
established. Tramadol Hydrochloride ODT was 
successfully prepared using Crospovidone (4%) 
and Sodium Starch glycolate (6%) as 
disintegrants. Based on the results, F10 batch was 
identified as the best formulation amongst all 
other formulations developed for orally 
disintegrating tablets. The tablets were evaluated 
for Pharmacopoeial and non – pharmacopoeial 
tests. The comparative evaluation of ODTs of 
Tramadol Hydrochloride with marketed product 
suggests that the reproducible F 10 batch shows a 
similar drug release profile with a similarity 
factor (f2) of 85.72.  
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